IFRX earnings: next report 2026-08-06, real EPS beat/miss history, analyst consensus Buy, P/E -2.59. Updated 2026-07-23.
InflaRx (IFRX) Research Hub
InflaRx (IFRX) trades on NASDAQ, DE in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.09 USD (0.00%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -2.59, market cap 0.13B. This hub links to the full technical, earnings and options research available for IFRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, DE |
| Last close | 2.09 USD (0.00%) |
| 52-week range | 1.55 USD – 2.5 USD |
| Trend regime | Range |
| 14-day RSI | 60.7 (Bullish) |
| Trailing P/E | -2.59 |
| Market cap | 0.13B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-06 |
Available research for IFRX
Covered Call on IFRX: how it works, illustrative setup around the real 2.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on IFRX: how it works, illustrative setup around the real 2.09 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on IFRX: how it works, illustrative setup around the real 2.09 USD price, max profit/loss, breakeven and when to use it. Educational.
IFRX technical analysis: range, last 2.09 USD, RSI 60.7, 52w range 1.55 USD–2.5 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is IFRX in?
InflaRx (IFRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, DE.
Is IFRX in an uptrend or downtrend?
As of 2026-09-11, IFRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is IFRX's trailing P/E ratio?
IFRX's trailing P/E is -2.59, with a market cap of 0.13B. See the earnings research page for full valuation detail.
When does IFRX next report earnings?
IFRX is next scheduled to report earnings on 2026-08-06, with a consensus EPS estimate of -0.08 USD.